0.68 - 0.75
0.33 - 0.86
12.80M / 4.66M (Avg.)
35.00 | 0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.74%
Revenue growth under 50% of 0425.HK's 38.64%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
44.00%
Gross profit growth above 1.5x 0425.HK's 25.80%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
175.08%
EBIT growth above 1.5x 0425.HK's 33.82%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
175.08%
Operating income growth above 1.5x 0425.HK's 33.82%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
228.07%
Net income growth above 1.5x 0425.HK's 28.19%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
228.28%
EPS growth above 1.5x 0425.HK's 28.07%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
228.28%
Diluted EPS growth above 1.5x 0425.HK's 28.07%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.00%
Slight or no buybacks while 0425.HK is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
-0.00%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-99.98%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-63.53%
Negative OCF growth while 0425.HK is at 319.19%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-57.45%
Negative FCF growth while 0425.HK is at 85.10%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-51.09%
Negative 10Y revenue/share CAGR while 0425.HK stands at 334.84%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
8.87%
5Y revenue/share CAGR under 50% of 0425.HK's 64.85%. Michael Burry would suspect a significant competitive gap or product weakness.
-51.44%
Negative 3Y CAGR while 0425.HK stands at 42.68%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-2256.08%
Negative 10Y OCF/share CAGR while 0425.HK stands at 366.12%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-2477.32%
Negative 5Y OCF/share CAGR while 0425.HK is at 34.83%. Joel Greenblatt would question the firm’s operational model or cost structure.
5.55%
3Y OCF/share CAGR under 50% of 0425.HK's 29.01%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-9.39%
Negative 10Y net income/share CAGR while 0425.HK is at 100.86%. Joel Greenblatt sees a major red flag in long-term profit erosion.
37.21%
Positive 5Y CAGR while 0425.HK is negative. John Neff might view this as a strong mid-term relative advantage.
153.00%
3Y net income/share CAGR above 1.5x 0425.HK's 6.20%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
65.53%
Below 50% of 0425.HK's 133.86%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
71.18%
5Y equity/share CAGR above 1.5x 0425.HK's 40.12%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
-9.27%
Negative 3Y equity/share growth while 0425.HK is at 18.46%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-99.92%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
No Data
No Data available this quarter, please select a different quarter.
-99.99%
Negative near-term dividend growth while 0425.HK invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
9.71%
AR growth is negative/stable vs. 0425.HK's 27.93%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
-1.97%
Inventory is declining while 0425.HK stands at 5.09%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-6.97%
Negative asset growth while 0425.HK invests at 10.87%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
6.25%
Similar to 0425.HK's 6.47%. Walter Schloss finds parallel capital usage or profit distribution strategies.
-16.11%
We’re deleveraging while 0425.HK stands at 11.55%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-32.73%
Our R&D shrinks while 0425.HK invests at 31.11%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-4.50%
We cut SG&A while 0425.HK invests at 18.28%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.